VICINITAS THERAPEUTICS
Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives. Its vision is to use its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit.
VICINITAS THERAPEUTICS
Industry:
Biotechnology Life Science Therapeutics
Founded:
2022-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.vicinitastx.com
Status:
Active
Total Funding:
65 M USD
Technology used in webpage:
Google Analytics Apache Google Analytics Classic Unified Layer CentOS Apache 2.2 BlueHost
Current Advisors List
Investors List
Berkeley Catalyst Fund (BCF)
Berkeley Catalyst Fund (BCF) investment in Series A - Vicinitas Therapeutics
The Mark Foundation for Cancer Research
The Mark Foundation for Cancer Research investment in Series A - Vicinitas Therapeutics
Droia Ventures
Droia Ventures investment in Series A - Vicinitas Therapeutics
GV
GV investment in Series A - Vicinitas Therapeutics
Andreessen Horowitz
Andreessen Horowitz investment in Series A - Vicinitas Therapeutics
Deerfield
Deerfield investment in Series A - Vicinitas Therapeutics
Official Site Inspections
http://www.vicinitastx.com Semrush global rank: 7.84 M Semrush visits lastest month: 432
- Host name: server-18-160-10-46.iad12.r.cloudfront.net
- IP address: 18.160.10.46
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vicinitas Therapeutics" on Search Engine
Vicinitas Therapeutics - Crunchbase Company Profile
Details. Industries. Biotechnology. Life Science. Therapeutics. Headquarters Regions San Francisco Bay Area, West Coast, Western US. Founded Date 2022. Operating Status …See details»
Our Team - Vicinitas Therapeutics
Tyzoon Nomanbhoy. VP of Chemical Biology. Read More. Janet Awaya. VP of Finance. Read More. Board of Directors. Dan Nomura. Founder. Cam Wheeler. Partner, Deerfield …See details»
News - Vicinitas Therapeutics
Read More. Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease.See details»
Vicinitas Therapeutics launches with $65 million for …
Jul 28, 2022 Vicinitas Therapeutics launches with $65 million for protein stabilization. The spin-out from UC Berkeley and Novartis saves needed proteins from destruction. by …See details»
Vicinitas Therapeutics | LinkedIn
Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquitinase Targeting Chimeras (DUBTACs).See details»
Platform Technologies - Vicinitas Therapeutics
Vicinitas Therapeutics has exclusively licensed the DUBTAC platform from both UC Berkeley and Novartis and aims to become the leading company in targeted protein …See details»
Vicinitas Therapeutics Launches to Advance Precision …
Jul 28, 2022 Berkeley, CA. It was announced today that Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to …See details»
Vicinitas Therapeutics Appoints Christian Hofmann, …
May 9, 2023 SOUTH SAN FRANCISCO, Calif.-- ( BUSINESS WIRE )--Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein …See details»
Vicinitas Therapeutics | IPIRA
Brief Description. Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs).See details»
Vicinitas Therapeutics Appoints Adam Hughes as Chief Scientific …
1 day ago Adam Hughes, Ph.D. Chief Scientific Officer, Vicinitas Therapeutics SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Vicinitas …See details»
Vicinitas Therapeutics Appoints Adam Hughes as Chief
19 hours ago Follow. SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Vicinitas Therapeutics, a biotechnology company advancing a …See details»
Vicinitas Therapeutics on LinkedIn: We're excited to announce the ...
We're excited to announce the appointment of Adam Hughes, Ph.D., as Chief Scientific Officer at Vicinitas! Adam's extensive experience discovering heterobifunctional …See details»
Vicinitas Therapeutics - Funding, Financials, Valuation & Investors
Vicinitas Therapeutics is funded by 6 investors. Berkeley Catalyst Fund (BCF) and The Mark Foundation for Cancer Research are the most recent investors.See details»
Vicinitas Therapeutics - Contacts, Employees, Board Members, …
About. Vicinitas Therapeutics has 2 current employee profiles, including Chief Executive Officer & Board of Directors Christian Hofmann. Vicinitas Therapeutics has 3 board …See details»
Vicinitas Therapeutics Launches With $65 Million in Series A …
Jul 28, 2022 SOUTH SAN FRANCISCO, Calif.-- ( BUSINESS WIRE )--Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein …See details»
Vicinitas Therapeutics | CipherBio
Vicinitas Therapeutics is the leading company developing next-generation medicines that impact patient lives. Stage: Public. Total Funds Raised: $0.00. Funding Products …See details»
Press Release Distribution and Management - GlobeNewswire
19 hours ago Vicinitas Therapeutics Appoints Adam Hughes as Chief Scientific Officer. SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Vicinitas …See details»
Vicinitas Therapeutics Launches With $65 Million in Series A …
South San Francisco–July 28, 2022–Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel …See details»
Vicinitas - Science
©Vicinitas 2022. Powered by Saberin Creative AboutSee details»
Privacy Policy - Vicinitas Therapeutics
Vicinitas Therapeutics gathers personal information (“PI”), such as names, addresses, zip/postal codes, e-mail addresses, when voluntarily submitted by a visitor. For example, …See details»